VOL.28, Suppl �]�X 2001　　ブリッジング・ストラテジー
Bridging Strategies

目 次
序　文	Stephen W.Lagakos 竹内正弘	iii
Faculty Members		iv-v
Program		vi-vii
Opening Remarks and Welcoming Address	佐藤登志郎	1
	Delcan P.Doogan	3-4
Global Harmonization	Chaired:James H.Ware	5-28
Global Harmonization and Achievements of ICH	Elain C.Esber	7-16
Impact of ICH Process and Guidelines	上田慶二	17-23
Discussion		25-8
Ethnic Differences	Chaired: 矢崎義雄	29-88
Drug Metabolism
Interethnic Differences in Drug Metabolism	石崎高志	31-51
Disease Presentation West vs East
Cardiovascular Disease in Asia: Mortality and Risk Factors	Jiang He	53-63
Dose Setting
Significance of Dose Setting Studies in the Bridging Study Strategy	内藤周幸	65-76
Discussion
Discussant Speech	村崎光邦	77-9
Discussant Speech	吉野 英	81-3
Panel Discussion		85-8
Bridging Strategies	Chaired: 井村裕夫	89-165
Bridging: Efficacy and Safety	川合眞一	91-103
Bridging: Methods and Special Populations
The Challenge of Bridging	James H.Ware	105-21
Bridging: Statistical Considerations (1)
Statistical Issues on Bridging Studies	竹内正弘	123-30
Bridging: Statistical Considerations (2)
Methodological Issues in Evaluation of Bridging Evidence 　　 　for Pharmaceutical Products	Jen-Pei Liu	131-42
Bridging Guidance	平山佳伸	143-51
Summary and Panel Discussion
Discussant Speech	内山明好	153-4
Summary and Panel Discussion		155-65
Future Strategies and Challenges	Chaired: Nan M.Laird	167-206
Bridging Western Data to Japan	坂井文彦	169-74
Bridging Japanese Data to West
Bridging Studies: Characterization of A Drug's Sensitivity 　　 　to Ethnic Factors	Richard Pazdur	175-8
Depression: Western and Japanese Difference	上島国利	179-88
Discussion
Discussant Speech	藤原康弘	189-95
Discussant Speech	島谷克義	197-9
Panel Discussion		201-6
Summary and Conclusion	Stephen W.Lagakos	209-16
	竹内正弘	217-9

「臨床評価」誌 トップページへ
「臨床評価」誌 各号の目次へ